Pacific Shuanglin Bio-pharmacy Co., LTD (SHE: 000403)

Market Cap	15.55B
Revenue (ttm)	2.84B
Net Income (ttm)	828.65M
Shares Out	731.07M
EPS (ttm)	1.14
PE Ratio	18.73
Forward PE	17.58
Dividend	0.30 (1.42%)
Ex-Dividend Date	Dec 17, 2024

Volume	5,487,319
Open	21.25
Previous Close	21.49
Day's Range	21.08 - 21.57
52-Week Range	19.46 - 30.64
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 24, 2025

About Pacific Shuanglin Bio-pharmacy Co., LTD

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in research, development, production, and sales of blood products in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), hepatitis B human immunoglobulin, tetanus human immunoglobulin, rabies patient immunoglobulin, and human coagulation factor. addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; and electronic product information consultation. The c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 2,426
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000403

Financial Performance

In 2023, Pacific Shuanglin Bio-pharmacy Co., LTD's revenue was 2.33 billion, a decrease of -3.18% compared to the previous year's 2.41 billion. Earnings were 612.11 million, an increase of 4.25%.